secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALPINE IMMUNE SCIENCES, INC. (—)
CIK:        0001626199
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001626199-24-000063
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vertex to acquire Alpine Immune for $65/share; Q1 net loss $17.9M
-----------------------------------------------------------------

- Vertex acquires Alpine for $65 per share in cash; transaction unanimously approved, expected to close in Q2 2024.
- Q1 net loss $17.9M ($0.28 per share) vs $13.3M loss in Q1 2023.
- Cash and investments $362.4M as of March 31, 2024; sufficient to fund operations into 2026.
- Collaboration revenue $7.0M, down from $9.4M; R&D expense up to $22.5M from $19.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626199/000162619924000063/0001626199-24-000063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626199/000162619924000063/alpn-20240509.htm
  HTML page:      https://secwatch.observer/filing/0001626199-24-000063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer